AXL and neoplasm: Interestingly, Fioramonti et al. [28] reported that cabozantinib, an inhibitor of multiple RTKs such as VEGFR2, AXL, and c‐MET, affects not only tumor cells but also osteoblasts, which induces RANKL expression, promoting tumor proliferation in the primary bone microenvironment.